JP2010068807A - ストレス評価方法 - Google Patents
ストレス評価方法 Download PDFInfo
- Publication number
- JP2010068807A JP2010068807A JP2009271893A JP2009271893A JP2010068807A JP 2010068807 A JP2010068807 A JP 2010068807A JP 2009271893 A JP2009271893 A JP 2009271893A JP 2009271893 A JP2009271893 A JP 2009271893A JP 2010068807 A JP2010068807 A JP 2010068807A
- Authority
- JP
- Japan
- Prior art keywords
- stress
- expression level
- gene
- clock
- living body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
【解決手段】生体から採取された細胞中におけるPer1遺伝子の発現レベルを測定する測定工程と、上記細胞中におけるPer1遺伝子の発現レベルの正常値と、上記測定工程で測定した発現レベルとを比較し、上記測定工程で測定した発現レベルが上記正常値より増加した場合に、上記生体にストレス負荷が与えられていると評価する評価工程とを有する。
【選択図】 図10
Description
従来、脳以外の末梢臓器において、時計関連遺伝子の発現レベルが日周期リズムを示すことが報告されている(Cell, 109, p307-p320; Nature, 417, p78-p83; Nature, 418, p534-p539; Jpn.J.Phamacol., 90, p263-p269; Neuroscience Letters, 256, p117-p119; American Journal of pathology, 158, p1793-1801)。そこで、先ず、肺(lung)、心臓(heart)、肝臓(liver)、胃(stomach)、脾臓(spleen)、腎臓(kidney)、精巣(testis)の各末梢臓器について、per1遺伝子及びper2遺伝子の発現レベルを測定した。
次に、ヒト血液を利用してper2遺伝子の発現レベルを測定した。具体的には、ZR Whole-Blood Total RNA Kit(Zymo Reserch 社)を用いて、ヒト白血球細胞からtotal RNAを抽出し、ヒトper2遺伝子のプライマー(センスプライマー:5'-GGCTCTCCTAGTTTTATTTCAAAACG-3'、アンチセンスプライマー:5'-GTGTGCATTCATCCGATGGA-3')を用いて上述と同様のプロトコルで逆転写PCRを行った。なお、本実験では、同一血液サンプルについて異なる日に計3回、per2遺伝子の発現レベルを測定した。
次に、本実施の形態の手法により十分なストレス負荷を与えることができるか否かを確認するために、ストレス負荷を与えたマウスと与えていないマウスとについて、ストレスホルモンの1つであるコルチコステロンの発現量を測定した。
次に、拘束ストレスによって時計関連遺伝子の発現レベルに変化が生じるか否かを確認するために、マウス血液を利用してper1遺伝子及びper2遺伝子の発現レベルの日周期リズムを測定した。
Claims (5)
- 生体から採取された細胞中におけるPer1遺伝子の発現レベルを測定する測定工程と、
上記細胞中におけるPer1遺伝子の発現レベルの正常値と、上記測定工程で測定した発現レベルとを比較し、上記測定工程で測定した発現レベルが上記正常値より増加した場合に、上記生体にストレス負荷が与えられていると評価する評価工程とを有するストレス評価方法。 - 上記ストレスは、上記細胞内でのコルチコステロンの上昇を伴う請求項1のストレス評価方法。
- 上記正常値は、所定期間に亘って測定した上記Per1遺伝子の発現レベルの平均値である請求項1のストレス評価方法。
- 上記細胞は、上記生体の血液中に存在する細胞である請求項1のストレス評価方法。
- 上記細胞は、午後0時から午後4時の間に生体から採取される請求項1のストレス評価方法。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009271893A JP5077332B2 (ja) | 2009-11-30 | 2009-11-30 | ストレス評価方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009271893A JP5077332B2 (ja) | 2009-11-30 | 2009-11-30 | ストレス評価方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003387025A Division JP4442197B2 (ja) | 2003-11-17 | 2003-11-17 | ストレス評価方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010068807A true JP2010068807A (ja) | 2010-04-02 |
| JP5077332B2 JP5077332B2 (ja) | 2012-11-21 |
Family
ID=42201171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009271893A Expired - Fee Related JP5077332B2 (ja) | 2009-11-30 | 2009-11-30 | ストレス評価方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5077332B2 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012205590A (ja) * | 2011-03-16 | 2012-10-25 | Taisho Pharmaceutical Co Ltd | 遺伝子発現を用いた疲労の判定方法 |
-
2009
- 2009-11-30 JP JP2009271893A patent/JP5077332B2/ja not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012205590A (ja) * | 2011-03-16 | 2012-10-25 | Taisho Pharmaceutical Co Ltd | 遺伝子発現を用いた疲労の判定方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5077332B2 (ja) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pan et al. | Tau accelerates α-synuclein aggregation and spreading in Parkinson’s disease | |
| Gabryelska et al. | Patients with obstructive sleep apnea present with chronic upregulation of serum HIF-1α protein | |
| Wu et al. | The TGF-β superfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation | |
| Chung et al. | Toxic and teratogenic effects of prenatal alcohol exposure on fetal development, adolescence, and adulthood | |
| Hiew et al. | TGF-β/Smad signalling in neurogenesis: implications for neuropsychiatric diseases | |
| Queen et al. | Improvements to healthspan through environmental enrichment and lifestyle interventions: where are we now? | |
| Böhm et al. | TGF-β contributes to impaired exercise response by suppression of mitochondrial key regulators in skeletal muscle | |
| Martínez et al. | miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea | |
| Chu et al. | The sigma-2 receptor and progesterone receptor membrane component 1 are different binding sites derived from independent genes | |
| Yan et al. | T cells are required for orthodontic tooth movement | |
| Nakaya et al. | Personality traits and cancer risk and survival based on Finnish and Swedish registry data. | |
| Cameron et al. | Alzheimer’s-related peptide amyloid-β plays a conserved role in angiogenesis | |
| Banskota et al. | Salicylates ameliorate intestinal inflammation by activating macrophage AMPK | |
| Nowak et al. | Nemaline myopathy caused by absence of α‐skeletal muscle actin | |
| Mazzola et al. | Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation | |
| Estébanez et al. | Resistance training diminishes the expression of exosome CD63 protein without modification of plasma miR-146a-5p and cfDNA in the elderly | |
| Kim et al. | Chronic sleep deprivation-induced proteome changes in astrocytes of the rat hypothalamus | |
| Tolusso et al. | Chemerin and PEDF are metaflammation-related biomarkers of disease activity and obesity in rheumatoid arthritis | |
| Qiao et al. | Lipopolysaccharide‐induced DNA damage response activates nuclear factor κB signalling pathway via GATA4 in dental pulp cells | |
| He et al. | Identification of the novel tooth-specific transcription factor AmeloD | |
| Singh et al. | The L-arginine transporter solute carrier family 7 member 2 mediates the immunopathogenesis of attaching and effacing bacteria | |
| Wang et al. | MiR-196a regulates high glucose-induced mesangial cell hypertrophy by targeting p27kip1 | |
| Kasper et al. | Perinatal obesity induces hepatic growth restriction with increased DNA damage response, senescence, and dysregulated Igf-1-Akt-Foxo1 signaling in male offspring of obese mice | |
| JP5077332B2 (ja) | ストレス評価方法 | |
| JP4442197B2 (ja) | ストレス評価方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120124 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120704 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120731 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120813 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150907 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150907 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |
